A Randomized, Single-Blind, Multicenter Phase 2 Study to Evaluate the Activity of 2 Dose Levels of Imetelstat in Subjects With Intermediate-2 or High-Risk Myelofibrosis (MF) Relapsed/Refractory to Janus Kinase (JAK) Inhibitor

Trial Profile

A Randomized, Single-Blind, Multicenter Phase 2 Study to Evaluate the Activity of 2 Dose Levels of Imetelstat in Subjects With Intermediate-2 or High-Risk Myelofibrosis (MF) Relapsed/Refractory to Janus Kinase (JAK) Inhibitor

Suspended
Phase of Trial: Phase II

Latest Information Update: 31 Oct 2017

At a glance

  • Drugs Imetelstat (Primary)
  • Indications Myelofibrosis
  • Focus Therapeutic Use
  • Acronyms IMbarkTM
  • Sponsors Geron Corporation; Janssen
  • Most Recent Events

    • 26 Oct 2017 Planned End Date changed from 1 May 2019 to 12 Jun 2019.
    • 26 Oct 2017 Planned primary completion date changed from 1 May 2018 to 4 May 2018.
    • 31 Jul 2017 According to a Geron Corporation media release, the company expects Janssen to perform an internal data review in the first quarter of 2018 to enable a potential protocol amendment to allow the long-term treatment and follow-up of patients, including for survival, beyond the current April 2018 per-protocol end-of-study date.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top